JP2020523327A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523327A5 JP2020523327A5 JP2019568003A JP2019568003A JP2020523327A5 JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5 JP 2019568003 A JP2019568003 A JP 2019568003A JP 2019568003 A JP2019568003 A JP 2019568003A JP 2020523327 A5 JP2020523327 A5 JP 2020523327A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- group
- heart failure
- compound selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 229940125634 FPR2 agonist Drugs 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 claims 1
- 102100021126 N-formyl peptide receptor 2 Human genes 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517211P | 2017-06-09 | 2017-06-09 | |
| US62/517,211 | 2017-06-09 | ||
| PCT/US2018/036631 WO2018227065A1 (en) | 2017-06-09 | 2018-06-08 | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523327A JP2020523327A (ja) | 2020-08-06 |
| JP2020523327A5 true JP2020523327A5 (enExample) | 2021-07-26 |
| JP7183193B2 JP7183193B2 (ja) | 2022-12-05 |
Family
ID=62779078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568003A Active JP7183193B2 (ja) | 2017-06-09 | 2018-06-08 | ピペリジノンホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11186544B2 (enExample) |
| EP (1) | EP3634412A1 (enExample) |
| JP (1) | JP7183193B2 (enExample) |
| KR (1) | KR102623473B1 (enExample) |
| CN (1) | CN110996950B (enExample) |
| WO (1) | WO2018227065A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2901471T3 (es) | 2015-12-10 | 2022-03-22 | Bristol Myers Squibb Co | Agonistas del receptor 2 de formilpéptido y del receptor 1 de formilpéptido de piperidinona |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| US11180490B2 (en) | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| KR102615095B1 (ko) | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| JP7398455B2 (ja) | 2018-11-26 | 2023-12-14 | ブリストル－マイヤーズ スクイブ カンパニー | ピラゾロンホルミルペプチド２受容体アゴニスト |
| ES2946673T3 (es) * | 2019-06-18 | 2023-07-24 | Bristol Myers Squibb Co | Agonistas del FPR2 de óxido de biaril dialquil fosfina |
| EP3789378A1 (en) * | 2019-09-06 | 2021-03-10 | Grünenthal GmbH | Piperidines or piperidones substituted with urea and heteroaryl |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6790845B2 (en) * | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
| US7678913B2 (en) | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| KR20140145203A (ko) | 2012-04-16 | 2014-12-22 | 알러간, 인코포레이티드 | 포르밀 펩타이드 수용체 2 조절물질로서 (2-우레이도아세트아미도)알킬 유도체 |
| SMT201800061T1 (it) | 2013-11-28 | 2018-05-02 | Kyorin Seiyaku Kk | Derivati dell'urea o loro sali farmacologicamente accettabili utili come io agonisti del recettore del peptide formile di tipo i (fprl-1) |
| ES2814126T3 (es) * | 2015-05-27 | 2021-03-26 | Kyorin Seiyaku Kk | Derivado de urea o sal farmacológicamente aceptable del mismo |
| CN107848962B (zh) | 2015-05-27 | 2021-04-09 | 杏林制药株式会社 | 脲衍生物或其药理学上可接受的盐 |
| MX2018005756A (es) | 2015-11-24 | 2018-08-01 | Squibb Bristol Myers Co | Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas. |
| ES2901471T3 (es) * | 2015-12-10 | 2022-03-22 | Bristol Myers Squibb Co | Agonistas del receptor 2 de formilpéptido y del receptor 1 de formilpéptido de piperidinona |
| ES2829550T3 (es) * | 2016-07-07 | 2021-06-01 | Bristol Myers Squibb Co | Ureas cíclicas espiro-condensadas como inhibidores de ROCK |
| TW201815762A (zh) * | 2016-09-21 | 2018-05-01 | 德商歌林達有限公司 | 經尿素及苯基取代之６員環狀胺或內醯胺 |
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| US11180490B2 (en) * | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| EP3762380B1 (en) * | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| ES2946673T3 (es) * | 2019-06-18 | 2023-07-24 | Bristol Myers Squibb Co | Agonistas del FPR2 de óxido de biaril dialquil fosfina |
-
2018
- 2018-06-08 EP EP18735093.9A patent/EP3634412A1/en not_active Withdrawn
- 2018-06-08 KR KR1020207000292A patent/KR102623473B1/ko active Active
- 2018-06-08 US US16/619,956 patent/US11186544B2/en active Active
- 2018-06-08 CN CN201880050610.9A patent/CN110996950B/zh not_active Expired - Fee Related
- 2018-06-08 JP JP2019568003A patent/JP7183193B2/ja active Active
- 2018-06-08 WO PCT/US2018/036631 patent/WO2018227065A1/en not_active Ceased